What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Eli Lilly's financial results for the third quarter and first nine months of 2007, and to provide updated financial guidance for the remainder of the year. It also details the company's use of non-GAAP financial measures for enhanced clarity.

Why is Eli Lilly using non-GAAP financial measures in this report?

Eli Lilly is using non-GAAP financial measures, such as adjusted pro forma net income and EPS, to provide investors with a clearer view of its ongoing operational performance. These measures exclude specific charges that are often volatile or one-time in nature (e.g., acquisition-related IPR&D, restructuring costs), which can mask underlying business trends when reported under GAAP.

What specific items are being excluded from the adjusted pro forma results?

The adjusted pro forma results exclude several significant items, including a charge for reduced product liability insurance recoveries, in-process research and development charges from acquisitions (Hypnion, Ivy Animal Health, ICOS, OSI Pharmaceuticals) and an in-licensing transaction with MacroGenics Inc., as well as restructuring charges related to manufacturing decisions.

How does the ICOS acquisition impact the reported results?

The ICOS acquisition closed in early 2007. For comparative purposes, Eli Lilly's pro forma presentation assumes that the acquisition was completed on January 1, 2006. This adjustment is made to allow investors to make more meaningful period-over-period comparisons of financial results between 2006 and 2007.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 18, 2007, to report its financial results for the third quarter and first nine months ended September 30, 2007. The filing primarily focuses on providing updated financial performance and future guidance. A key aspect of this report is the company's use of non-GAAP financial measures, such as adjusted pro forma net income and earnings per share, to offer a clearer view of ongoing operations and enable more meaningful period-over-period comparisons. These adjustments exclude significant one-time charges, including product liability insurance adjustments, in-process research and development (IPR&D) from acquisitions, restructuring charges, and IPR&D from specific licensing agreements. Investors should note that Lilly is providing both GAAP and adjusted pro forma financial information and forward-looking guidance. The company emphasizes that these non-GAAP measures are intended to supplement, not replace, GAAP figures, aiding in the evaluation of underlying business trends. The adjusted pro forma presentation also reflects the assumption that the ICOS acquisition occurred on January 1, 2006, to facilitate better comparison between 2006 and 2007 results.

Key Highlights

1Eli Lilly reported third quarter and nine-month results as of September 30, 2007.
2The company utilized adjusted pro forma financial measures (non-GAAP) for net income and EPS to present ongoing operational performance.
3Adjusted results exclude charges related to product liability insurance, IPR&D from Hypnion, Ivy Animal Health, ICOS, and OSI Pharmaceuticals acquisitions/licensing, and manufacturing restructuring costs.
4The pro forma presentation assumes the ICOS acquisition closed on January 1, 2006, for comparative purposes.
5Lilly provided updated financial expectations for the fourth quarter and full year 2007, including both GAAP and adjusted pro forma EPS guidance.
6The company believes non-GAAP measures help investors evaluate ongoing operations and identify trends masked by unusual items.
7The press release and related financial statements (Exhibit 99.1) are attached to the 8-K.

ELI LILLY & Co 8-K Report, Financial Results (Oct 19, 2007)

Summary

Key Highlights

Frequently Asked Questions